BioCentury
ARTICLE | Clinical News

Ad-IL-12: Phase I started

May 11, 2015 7:00 AM UTC

Ziopharm began an open-label Phase I trial to evaluate a single intratumoral injection of Ad-IL-12 in combination with 20, 30, 80 or 120 mg oral veledimex, an activator ligand, once daily for 14 days ...